425: Mallinckrodt and Endo Pharmaceuticals Announce Merger to Create $3.6 Billion Generics and Branded Pharmaceutical Powerhouse

Mallinckrodt and Endo Pharmaceuticals are merging to create a combined company with approximately $3.6 billion in revenue, aiming for a stronger balance sheet and increased investment opportunities.

Summary

• Mallinckrodt announced its Q4 and full-year 2024 results and the planned merger with Endo Pharmaceuticals.
• 2024 was described as an 'amazing year' with the company hitting the high end of its revenue guidance and the midpoint of its updated EBITDA guidance, even with only 11 months of Therakos sales.
• Acthar experienced double-digit growth, exceeding initial expectations of low single-digit growth.
• The specialty generics business also showed double-digit growth, outperforming the market, particularly in solid oral doses.
• The merger with Endo is seen as a way to create a stronger company with a combined revenue of approximately $3.6 billion.
• The combined generics business is estimated to generate $1.7 billion in revenue, making it one of the largest in the U.S.
• The brand business is also expected to be significant, with approximately $1.7 billion in revenue and over 10 brands.
• The net debt of the new company at closing is estimated to be about 2.3 times EBITDA, allowing for more investment in innovation.
• The transaction is expected to close in the second half of the year, pending regulatory and shareholder approvals.
• Mallinckrodt's EBITDA guidance for 2025 is $480 to $520 million, with a midpoint of $500 million, representing single-digit growth.
• The formal headquarters of the company will be in Dublin, Ireland, but the U.S. headquarters location is yet to be determined.
• The plan is to separate the generics business into a standalone company, potentially through a spin-out.
• The leadership team for the merged company will likely be announced closer to the transaction's closing.
• The new company intends to list on the New York Stock Exchange soon after closing.
• Mallinckrodt believes the merger will create a more exciting company to work for, helping more patients than ever before.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook due to strong financial performance, successful product launches, and the potential benefits of the merger. While there are inherent risks and uncertainties, the overall tone is optimistic and confident.

Positives

• Mallinckrodt had a strong financial performance in 2024, exceeding expectations for revenue and EBITDA.
• Acthar's growth signifies a successful turnaround and stabilization of the product.
• The specialty generics business is performing well, contributing significantly to overall growth.
• The merger with Endo is expected to create a stronger, more diversified company with increased financial flexibility.
• The combined company will have a stronger balance sheet, allowing for more investment in innovation and growth initiatives.
• The plan to separate the generics business could unlock value and allow it to operate more effectively as a standalone entity.
• The majority of the combined company's manufacturing plants are located in the U.S., which could be advantageous in light of potential tariffs.

Negatives

• The location of the U.S. headquarters for the combined company is yet to be determined, creating uncertainty for employees.
• The leadership team for the merged company will not be announced until closer to the closing date, causing potential anxiety among employees.
• Integration of the two companies will require significant effort and could present challenges.
• The transaction is subject to regulatory and shareholder approvals, which could delay or prevent the merger from happening.

Risks

• The integration of Mallinckrodt and Endo's businesses may be more difficult and costly than anticipated.
• The expected benefits and synergies of the merger may not be fully realized or may take longer to achieve.
• The separation of the generics business may not be successful or may not unlock the expected value.
• Regulatory approvals for the merger may be delayed or may be subject to conditions that are not anticipated.
• The combined company will have increased indebtedness, which could limit its financial flexibility.
• Potential litigation related to the merger could be costly and time-consuming.
• The company faces risks related to its business, including competition, pricing pressures, and regulatory scrutiny.

Future Outlook

Mallinckrodt anticipates single-digit growth in 2025, with a focus on driving Acthar, the finished dose business in GX, the rollout of Evolve, and Terlivaz. The merger with Endo is expected to create a stronger company with increased opportunities for innovation and growth.

Management Comments

• Sigurdur Olafsson: '2024 was amazing year. Really outstanding year for all of us, and thanks to you we really delivered on our promises.'
• Sigurdur Olafsson: 'This is a significant milestone for us, and how we think about it, it is a highly complementary companies.'
• Stephen Welch: 'Change is a scary thing, and I'm sure many of you are feeling that, but I will say we have a boss that has delivered on every single promise that he made to us on day one.'
• Lisa French: 'Congratulations to the specialty brands team for delivering, really, on an extraordinary year.'

Industry Context

The merger reflects a trend of consolidation in the pharmaceutical industry, as companies seek to achieve greater scale, diversify their product portfolios, and improve their financial strength. The combined company will be a significant player in both the generics and branded pharmaceutical markets, competing with other large pharmaceutical companies.

Comparison to Industry Standards

• A generics business with $1.7 billion in revenue would place the combined entity among the top generics players in the US, competing with companies like Teva, Viatris, and Sun Pharma.
• A branded business with $1.7 billion in revenue would position the company as a mid-sized player in the branded pharmaceutical space, similar to companies like Horizon Therapeutics or Lundbeck.
• A net debt to EBITDA ratio of 2.3x is generally considered healthy and provides financial flexibility for future investments, comparing favorably to companies with higher leverage.

Stakeholder Impact

• Shareholders: Expected to benefit from the increased value and growth potential of the combined company.
• Employees: Potential for new opportunities and career advancement within the larger organization, but also uncertainty regarding job security and organizational changes.
• Patients: Access to a broader range of pharmaceutical products and therapies.
• Customers: Continued access to high-quality products and services.
• Suppliers: Potential for increased business opportunities with the larger combined company.
• Creditors: Improved financial stability and creditworthiness of the combined company.

Next Steps

• Obtain regulatory and shareholder approvals for the merger.
• Form an integration team to plan the integration of Mallinckrodt and Endo's businesses.
• Determine the location of the U.S. headquarters for the combined company.
• Announce the leadership team for the merged company.
• Prepare for the listing of the new company on the New York Stock Exchange.
• Work towards the separation of the generics business into a standalone company.
• Focus on executing the 2025 business plan and delivering strong financial results.

Key Dates

Keywords

merger, Mallinckrodt, Endo Pharmaceuticals, generics, Acthar, specialty brands, EBITDA, revenue, pharmaceuticals, INOmax, SelfJect, Terlivaz